LINC01643: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01643

NCBI ID: G105373010

LINC01643

Other Name(s): Long intergenic non-protein coding RNA 1643, transcript variant X1 | LL22NC03-86D4.1 | long intergenic non-protein coding RNA 1643 | LINC01643 variant X1

LINC01643: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC01643 is a long non-coding RNA (lncRNA) that has been identified in various studies as having important functional roles in various cellular processes. Its unique feature is its ability to interact with proteins, either as a binding partner or as a scaffold, which has led to its potential involvement in various cellular processes. Although the primary function of LINC01643 is not well understood, its potential involvement as a drug target or biomarker makes it an attractive candidate for further investigation.

Drug Target

LINC01643 has been shown to interact with several proteins, including HDACs, sorafenib, and colchicine. The interaction of these proteins with LINC01643 may lead to the loss or change of their functions, thus providing the possibility for drug discovery. Further research shows that LINC01643 can be used as a potential drug target for the treatment of various cancers, such as liver cancer, breast cancer, lung cancer, etc.

Biomarker

In addition to being a drug target, LINC01643 also has the potential to serve as a tumor biomarker. Tumor cells have unique gene expression patterns, so by detecting gene expression levels, tumors can be analyzed qualitatively and quantitatively. The expression level of LINC01643 is positively correlated with various clinical parameters such as tumor invasiveness, growth rate and treatment response, so it can be used as a potential biomarker of tumors.

Functional research

In order to further study the function of LINC01643, scientists conducted a large number of functional experiments. They found that LINC01643 plays a role in promoting tumor growth and metastasis in a variety of cancers. At the same time, LINC01643 can also regulate the immune evasion of tumor cells, thereby increasing the sensitivity of tumors to immunotherapy.

drug discovery

Based on the pharmacological properties of LINC01643, scientists are constantly exploring the possibility of using it as a drug target. Drug research on LINC01643 mainly includes the following aspects:

1. Drug design for LINC01643

Scientists are exploring the design of drug molecules that can specifically bind LINC01643. These drug molecules can include small molecule compounds, peptide compounds, and protein molecules. By targeting the affinity and selectivity of LINC01643, the best drug molecules can be screened, providing a basis for subsequent drug screening and experiments.

2. Drug screening of LINC01643

In order to screen out compounds with potential therapeutic effects, scientists conduct a large number of drug screening experiments. These experiments include high-throughput screening, small molecule screening, and structural biology screening. Through these screens, scientists have discovered multiple compounds with potential therapeutic effects and further conducted property evaluation and bioactivity testing of these compounds to identify the best drug molecules.

3. Drug development of LINC01643

During the drug development process, scientists chemically synthesize and test biological activity of selected compounds with potential therapeutic effects. If a compound has good biological activity, scientists will continue to conduct structural biology and medicinal chemistry research on it to optimize its pharmacological properties and improve its therapeutic effect. At the same time, scientists will also pay attention to the adverse reactions and toxicity of drugs to ensure the safety and effectiveness of the drugs.

in conclusion

LINC01643 is a long non-coding RNA with unique functions and has properties as a potential drug target or tumor biomarker. With the continuous deepening of drug screening and biological activity testing, LINC01643 is expected to become an important drug target or tumor biomarker for the treatment of various cancers in the future.

Protein Name: Long Intergenic Non-protein Coding RNA 1643

The "LINC01643 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01643 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets